Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- talimogene laherparepvec
- Xalkori (crizotinib)
Interactions between your drugs
crizotinib talimogene laherparepvec
Applies to: Xalkori (crizotinib), talimogene laherparepvec
If you are currently being treated or have recently been treated with crizotinib, you should let your doctor know before receiving talimogene laherparepvec. Depending on the dose and length of time you have been on crizotinib, you may be at risk for developing a potentially life-threatening herpes infection from exposure to talimogene laherparepvec. In some situations, your doctor may want to delay treatment with talimogene laherparepvec to give your body time to recover from the effects of crizotinib therapy. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
crizotinib food
Applies to: Xalkori (crizotinib)
Do not consume grapefruit or grapefruit juice during treatment with crizotinib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of crizotinib to dangerous levels and cause an irregular heart rhythm that may be serious. You should seek immediate medical attention if you develop sudden dizziness, lightheadedness, fainting, shortness of breath, or fast or pounding heartbeats during treatment with crizotinib. You may take crizotinib with or without food, but take it the same time each day. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Keytruda
Keytruda is used to treat melanoma, non-small cell lung cancer, malignant pleural mesothelioma ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Dacarbazine
Dacarbazine is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Ipilimumab
ipilimumab (Yervoy) is an immunotherapy used for melanoma, renal cell carcinoma, non-small cell ...
Dabrafenib
Dabrafenib is used for low-grade glioma, melanoma, metastatic, non small cell lung cancer, solid ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.